The role of endocannabinoids in pain modulation and the therapeutic potential of inhibiting their enzymatic degradation

Current Pharmaceutical Biotechnology

Volumn 12, Issue 10, 2011, Pages 1644-1659

  Alvarez Jaimes, L J ^a   Palmer, J A ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

2 arachidonoylglycerol (2 AG); Anandamide (AEA); Cannabinoid; Endocannabinoid; Fatty acid amide hydrolase (FAAH)

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 2 ARACHIDONOYLGLYCEROL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; ALPHA KETOHETEROCYCLE; ANANDAMIDE; ARVANIL; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CARBAMIC ACID; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; ENDOCANNABINOID; FATTY ACID AMIDASE; FATTY ACID AMIDASE INHIBITOR; JNJ 1661010; LIPID; MONOACYLGLYCERIDE LIPASE; N (3 FURYLMETHYL)ARACHIDONAMIDE; N (4 HYDROXYPHENYL)ARACHIDONAMIDE; NOLADIN ETHER; PF 04457845; PF 3845; PF 465; PF 662; PF 750; RIMONABANT; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG; UREA;

ALLODYNIA; ANTINOCICEPTION; ARTICLE; BINDING AFFINITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; ENZYME DEGRADATION; ENZYME INHIBITION; HUMAN; HYDROLYSIS; INFLAMMATION; NEUROPATHIC PAIN; NONHUMAN; PAIN ASSESSMENT; PHASE 1 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; VISCERAL PAIN;

EID: 80053501638     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920111798357357     Document Type: Article

References (175)

1. Devane, W.A.; Hanus, L.; Breuer, A.; Pertwee, R.G.; Stevenson, L.A.; Griffin, G.; Gibson, D.; Mandelbaum, A.; Etinger, A.; Mechoulam, R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science, 1992, 258(5090), 1946-1949.
2. Felder, C.C.; Briley, E.M.; Axelrod, J.; Simpson, J.T.; Mackie, K.; Devane, W.A. Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction. Proc. Natl. Acad. Sci. USA, 1993, 90(16), 7656-7660.
3. Ahn, K.; McKinney, M.K.; Cravatt, B.F. Enzymatic pathways that regulate endocannabinoid signaling in the nervous system. Chem. Rev., 2008, 108(5), 1687-1707.
4. Schmid, H.H.; Schmid, P.C.; Berdyshev, E.V. Cell signaling by endocannabinoids and their congeners: questions of selectivity and other challenges. Chem. Phys. Lipids, 2002, 121(1-2), 111-134.
5. Okamoto, Y.; Morishita, J.; Tsuboi, K.; Tonai, T.; Ueda, N. Molecular characterization of a phospholipase D generating anandamide and its congeners. J. Biol. Chem., 2004, 279(7), 5298-5305.
6. Di Marzo, V.; Fontana, A.; Cadas, H.; Schinelli, S.; Cimino, G.; Schwartz, J.C.; Piomelli, D. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature, 1994, 372(6507), 686-691.
7. Cadas, H.; di Tomaso, E.; Piomelli, D. Occurrence and biosynthesis of endogenous cannabinoid precursor, N-arachidonoyl phosphatidylethanolamine, in rat brain. J. Neurosci., 1997, 17(4), 1226- 1242.
8. Kreitzer, A.C.; Regehr, W.G. Retrograde inhibition of presynaptic calcium influx by endogenous cannabinoids at excitatory synapses onto Purkinje cells. Neuron, 2001, 29(3), 717-727.
9. Wilson, R.I.; Nicoll, R.A. Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature, 2001, 410(6828), 588-592.
10. Ohno-Shosaku, T.; Maejima, T.; Kano, M. Endogenous cannabinoids mediate retrograde signals from depolarized postsynaptic neurons to presynaptic terminals. Neuron, 2001, 29(3), 729-738.
11. Bisogno, T.; Berrendero, F.; Ambrosino, G.; Cebeira, M.; Ramos, J.A.; Fernandez-Ruiz, J.J.; Di Marzo, V. Brain regional distribution of endocannabinoids: implications for their biosynthesis and biological function. Biochem. Biophys. Res. Commun., 1999, 256(2), 377-380.
12. Yang, H.Y.; Karoum, F.; Felder, C.; Badger, H.; Wang, T.C.; Markey, S.P. GC/MS analysis of anandamide and quantification of Narachidonoylphosphatidylethanolamides in various brain regions, spinal cord, testis, and spleen of the rat. J. Neurochem., 1999, 72(5), 1959-1968.
13. Matsuda, L.A.; Lolait, S.J.; Brownstein, M.J.; Young, A.C.; Bonner, T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature, 1990, 346(6284), 561-564.
14. Munro, S.; Thomas, K.L.; Abu-Shaar, M. Molecular characterization of a peripheral receptor for cannabinoids. Nature, 1993, 365(6441), 61-65.
15. Herkenham, M.; Lynn, A.B.; Johnson, M.R.; Melvin, L.S.; de Costa, B.R.; Rice, K.C. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J. Neurosci., 1991, 11(2), 563-583.
16. Herkenham, M.; Lynn, A.B.; Little, M.D.; Johnson, M.R.; Melvin, L.S.; de Costa, B.R.; Rice, K.C. Cannabinoid receptor localization in brain. Proc. Natl. Acad. Sci. USA, 1990, 87(5), 1932-1936.
17. Glass, M.; Dragunow, M.; Faull, R.L. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience, 1997, 77(2), 299-318.
18. Lynn, A.B.; Herkenham, M. Localization of cannabinoid receptors and nonsaturable high-density cannabinoid binding sites in peripheral tissues of the rat: implications for receptor-mediated immune modulation by cannabinoids. J. Pharmacol. Exp. Ther., 1994, 268(3), 1612-1623.
19. Gong, J.P.; Onaivi, E.S.; Ishiguro, H.; Liu, Q.R.; Tagliaferro, P.A.; Brusco, A.; Uhl, G.R. Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. Brain Res., 2006, 1071(1), 10-23.
20. Van Sickle, M.D.; Duncan, M.; Kingsley, P.J.; Mouihate, A.; Urbani, P.; Mackie, K.; Stella, N.; Makriyannis, A.; Piomelli, D.; Davison, J.S.; Marnett, L.J.; Di Marzo, V.; Pittman, Q.J.; Patel, K.D.; Sharkey, K.A. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science, 2005, 310(5746), 329-332.
21. Pertwee, R.G. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol. Ther., 1997, 74(2), 129-180.
22. Zygmunt, P.M.; Petersson, J.; Andersson, D.A.; Chuang, H.; Sorgard, M.; Di Marzo, V.; Julius, D.; Hogestatt, E.D. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature, 1999, 400(6743), 452-457.
23. Ryberg, E.; Larsson, N.; Sjogren, S.; Hjorth, S.; Hermansson, N.O.; Leonova, J.; Elebring, T.; Nilsson, K.; Drmota, T.; Greasley, P.J. The orphan receptor GPR55 is a novel cannabinoid receptor. Br. J. Pharmacol., 2007, 152(7), 1092-1101.
24. Smart, D.; Gunthorpe, M.J.; Jerman, J.C.; Nasir, S.; Gray, J.; Muir, A.I.; Chambers, J.K.; Randall, A.D.; Davis, J.B. The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1). Br. J. Pharmacol., 2000, 129(2), 227-230.
25. Jensen, T.S.; Madsen, C.S.; Finnerup, N.B. Pharmacology and treatment of neuropathic pains. Curr. Opin. Neurol., 2009, 22(5), 467-474.
26. Varvel, S.A.; Bridgen, D.T.; Tao, Q.; Thomas, B.F.; Martin, B.R.; Lichtman, A.H. Delta9-tetrahydrocannbinol accounts for the antinociceptive, hypothermic, and cataleptic effects of marijuana in mice. J. Pharmacol. Exp. Ther., 2005, 314(1), 329-337.
27. Bridges, D.; Ahmad, K.; Rice, A.S. The synthetic cannabinoid WIN55,212-2 attenuates hyperalgesia and allodynia in a rat model of neuropathic pain. Br. J. Pharmacol., 2001, 133(4), 586-594.
28. Tsou, K.; Lowitz, K.A.; Hohmann, A.G.; Martin, W.J.; Hathaway, C.B.; Bereiter, D.A.; Walker, J.M. Suppression of noxious stimulus- evoked expression of Fos protein-like immunoreactivity in rat spinal cord by a selective cannabinoid agonist. Neuroscience, 1996, 70(3), 791-798.
29. Kosersky, D.S.; Dewey, W.L.; Harris, L.S. Antipyretic, analgesic and anti-inflammatory effects of delta 9-tetrahydrocannabinol in the rat. Eur. J. Pharmacol., 1973, 24(1), 1-7.
30. Rawls, S.M.; Schroeder, J.A.; Ding, Z.; Rodriguez, T.; Zaveri, N. NOP receptor antagonist, JTC-801, blocks cannabinoid-evoked hypothermia in rats. Neuropeptides, 2007, 41(4), 239-247.
31. Smith, P.B.; Compton, D.R.; Welch, S.P.; Razdan, R.K.; Mechoulam, R.; Martin, B.R. The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. J. Pharmacol. Exp. Ther., 1994, 270(1), 219-227.
32. Welch, S.P.; Huffman, J.W.; Lowe, J. Differential blockade of the antinociceptive effects of centrally administered cannabinoids by SR141716A. J. Pharmacol. Exp. Ther., 1998, 286(3), 1301-1308.
33. Guindon, J.; Beaulieu, P. Antihyperalgesic effects of local injections of anandamide, ibuprofen, rofecoxib and their combinations in a model of neuropathic pain. Neuropharmacology, 2006, 50(7), 814-823.
34. Jayamanne, A.; Greenwood, R.; Mitchell, V.A.; Aslan, S.; Piomelli, D.; Vaughan, C.W. Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models. Br. J. Pharmacol., 2006, 147(3), 281-288.
35. Jhaveri, M.D.; Richardson, D.; Kendall, D.A.; Barrett, D.A.; Chapman, V. Analgesic effects of fatty acid amide hydrolase inhibition in a rat model of neuropathic pain. J. Neurosci., 2006, 26(51), 13318-13327.
36. La Rana, G.; Russo, R.; Campolongo, P.; Bortolato, M.; Mangieri, R.A.; Cuomo, V.; Iacono, A.; Raso, G.M.; Meli, R.; Piomelli, D.; Calignano, A. Modulation of neuropathic and inflammatory pain by the endocannabinoid transport inhibitor AM404 [N-(4- hydroxyphenyl)-eicosa-5,8,11,14-tetraenamide]. J. Pharmacol. Exp. Ther., 2006, 317(3), 1365-1371.
37. Cravatt, B.F.; Demarest, K.; Patricelli, M.P.; Bracey, M.H.; Giang, D.K.; Martin, B.R.; Lichtman, A.H. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc. Natl. Acad. Sci. USA, 2001, 98(16), 9371-9376.
38. Agarwal, N.; Pacher, P.; Tegeder, I.; Amaya, F.; Constantin, C.E.; Brenner, G.J.; Rubino, T.; Michalski, C.W.; Marsicano, G.; Monory, K.; Mackie, K.; Marian, C.; Batkai, S.; Parolaro, D.; Fischer, M.J.; Reeh, P.; Kunos, G.; Kress, M.; Lutz, B.; Woolf, C.J.; Kuner, R. Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Nat. Neurosci., 2007, 10(7), 870-879.
39. Hohmann, A.G.; Herkenham, M. Localization of central cannabinoid CB1 receptor messenger RNA in neuronal subpopulations of rat dorsal root ganglia: a double-label in situ hybridization study. Neuroscience, 1999, 90(3), 923-931.
40. Lever, I.J.; Robinson, M.; Cibelli, M.; Paule, C.; Santha, P.; Yee, L.; Hunt, S.P.; Cravatt, B.F.; Elphick, M.R.; Nagy, I.; Rice, A.S. Localization of the endocannabinoid-degrading enzyme fatty acid amide hydrolase in rat dorsal root ganglion cells and its regulation after peripheral nerve injury. J. Neurosci., 2009, 29(12), 3766- 3780.
41. Mitrirattanakul, S.; Ramakul, N.; Guerrero, A.V.; Matsuka, Y.; Ono, T.; Iwase, H.; Mackie, K.; Faull, K.F.; Spigelman, I. Sitespecific increases in peripheral cannabinoid receptors and their endogenous ligands in a model of neuropathic pain. Pain, 2006, 126(1-3), 102-114.
42. Hohmann, A.G.; Martin, W.J.; Tsou, K.; Walker, J.M. Inhibition of noxious stimulus-evoked activity of spinal cord dorsal horn neurons by the cannabinoid WIN 55,212-2. Life Sci., 1995, 56(23-24), 2111-2118.
43. Strangman, N.M.; Walker, J.M. Cannabinoid WIN 55,212-2 inhibits the activity-dependent facilitation of spinal nociceptive responses. J. Neurophysiol., 1999, 82(1), 472-477.
44. Hohmann, A.G.; Tsou, K.; Walker, J.M. Cannabinoid suppression of noxious heat-evoked activity in wide dynamic range neurons in the lumbar dorsal horn of the rat. J. Neurophysiol., 1999, 81(2), 575-583.
45. Martin, W.J.; Patrick, S.L.; Coffin, P.O.; Tsou, K.; Walker, J.M. An examination of the central sites of action of cannabinoidinduced antinociception in the rat. Life Sci., 1995, 56(23-24), 2103-2109.
46. Martin, W.J.; Tsou, K.; Walker, J.M. Cannabinoid receptormediated inhibition of the rat tail-flick reflex after microinjection into the rostral ventromedial medulla. Neurosci. Lett., 1998, 242(1), 33-36.
47. Finn, D.P.; Jhaveri, M.D.; Beckett, S.R.; Roe, C.H.; Kendall, D.A.; Marsden, C.A.; Chapman, V. Effects of direct periaqueductal grey administration of a cannabinoid receptor agonist on nociceptive and aversive responses in rats. Neuropharmacology, 2003, 45(5), 594-604.
48. Walker, J.M.; Huang, S.M.; Strangman, N.M.; Tsou, K.; Sanudo- Pena, M.C. Pain modulation by release of the endogenous cannabinoid anandamide. Proc. Natl. Acad. Sci. USA, 1999, 96(21), 12198-12203.
49. Petrosino, S.; Palazzo, E.; de Novellis, V.; Bisogno, T.; Rossi, F.; Maione, S.; Di Marzo, V. Changes in spinal and supraspinal endocannabinoid levels in neuropathic rats. Neuropharmacology, 2007, 52(2), 415-422.
50. Kidd, B.L.; Urban, L.A. Mechanisms of inflammatory pain. Br. J. Anaesth., 2001, 87(1), 3-11.
51. Smith, F.L.; Fujimori, K.; Lowe, J.; Welch, S.P. Characterization of delta9-tetrahydrocannabinol and anandamide antinociception in nonarthritic and arthritic rats. Pharmacol. Biochem. Behav., 1998, 60(1), 183-191.
52. Ahn, K.; Johnson, D.S.; Mileni, M.; Beidler, D.; Long, J.Z.; McKinney, M.K.; Weerapana, E.; Sadagopan, N.; Liimatta, M.; Smith, S.E.; Lazerwith, S.; Stiff, C.; Kamtekar, S.; Bhattacharya, K.; Zhang, Y.; Swaney, S.; Van Becelaere, K.; Stevens, R.C.; Cravatt, B.F. Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain. Chem. Biol., 2009, 16(4), 411-420.
53. Jaggar, S.I.; Hasnie, F.S.; Sellaturay, S.; Rice, A.S. The antihyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. Pain, 1998, 76(1-2), 189-199.
54. Richardson, J.D.; Kilo, S.; Hargreaves, K.M. Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. Pain, 1998, 75(1), 111-119.
55. Farquhar-Smith, W.P.; Rice, A.S. Administration of endocannabinoids prevents a referred hyperalgesia associated with inflammation of the urinary bladder. Anesthesiology, 2001, 94(3), 507-513 discussion 506A.
56. Mechoulam, R.; Ben-Shabat, S.; Hanus, L.; Ligumsky, M.; Kaminski, N.E.; Schatz, A.R.; Gopher, A.; Almog, S.; Martin, B.R.; Compton, D.R.; Pertwee, R.G.; Griffin, G.; Bayewitch, M.; Barg, J.; Vogel, Z. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol., 1995, 50(1), 83-90.
57. Sugiura, T.; Kondo, S.; Sukagawa, A.; Nakane, S.; Shinoda, A.; Itoh, K.; Yamashita, A.; Waku, K. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Commun., 1995, 215(1), 89-97.
58. Bisogno, T.; Sepe, N.; Melck, D.; Maurelli, S.; De Petrocellis, L.; Di Marzo, V. Biosynthesis, release and degradation of the novel endogenous cannabimimetic metabolite 2-arachidonoylglycerol in mouse neuroblastoma cells. Biochem. J., 1997, 322(2), 671-677.
59. Stella, N.; Schweitzer, P.; Piomelli, D. A second endogenous cannabinoid that modulates long-term potentiation. Nature, 1997, 388(6644), 773-778.
60. Piomelli, D. The molecular logic of endocannabinoid signalling. Nat. Rev. Neurosci., 2003, 4(11), 873-884.
61. Sugiura, T.; Yoshinaga, N.; Waku, K. Rapid generation of 2- arachidonoylglycerol, an endogenous cannabinoid receptor ligand, in rat brain after decapitation. Neurosci. Lett., 2001, 297(3), 175-178.
62. Huang, S.M.; Strangman, N.M.; Walker, J.M. Liquid chromatographic- mass spectrometric measurement of the endogenous cannabinoid 2-arachidonylglycerol in the spinal cord and peripheral nervous system. Zhongguo Yao Li Xue Bao, 1999, 20(12), 1098-1102.
63. 2+-dependent and -independent mechanisms. FEBS Lett., 1998, 429(2), 152-156.
64. Katona, I.; Urban, G.M.; Wallace, M.; Ledent, C.; Jung, K.M.; Piomelli, D.; Mackie, K.; Freund, T.F. Molecular composition of the endocannabinoid system at glutamatergic synapses. J. Neurosci., 2006, 26(21), 5628-5637.
65. Yoshida, T.; Fukaya, M.; Uchigashima, M.; Miura, E.; Kamiya, H.; Kano, M.; Watanabe, M. Localization of diacylglycerol lipasealpha around postsynaptic spine suggests close proximity between production site of an endocannabinoid, 2-arachidonoyl-glycerol, and presynaptic cannabinoid CB1 receptor. J. Neurosci., 2006, 26(18), 4740-4751.
66. Matyas, F.; Urban, G.M.; Watanabe, M.; Mackie, K.; Zimmer, A.; Freund, T.F.; Katona, I. Identification of the sites of 2- arachidonoylglycerol synthesis and action imply retrograde endocannabinoid signaling at both GABAergic and glutamatergic synapses in the ventral tegmental area. Neuropharmacology, 2008, 54(1), 95-107.
67. Watanabe, H.; Vriens, J.; Prenen, J.; Droogmans, G.; Voets, T.; Nilius, B. Anandamide and arachidonic acid use epoxyeicosatrienoic acids to activate TRPV4 channels. Nature, 2003, 424(6947), 434-438.
68. Hohmann, A.G.; Suplita, R.L.; Bolton, N.M.; Neely, M.H.; Fegley, D.; Mangieri, R.; Krey, J.F.; Walker, J.M.; Holmes, P.V.; Crystal, J.D.; Duranti, A.; Tontini, A.; Mor, M.; Tarzia, G.; Piomelli, D. An endocannabinoid mechanism for stress-induced analgesia. Nature, 2005, 435(7045), 1108-1112.
69. Kinsey, S.G.; Long, J.Z.; O'Neal, S.T.; Abdullah, R.A.; Poklis, J.L.; Boger, D.L.; Cravatt, B.F.; Lichtman, A.H. Blockade of endocannabinoid- degrading enzymes attenuates neuropathic pain. J. Pharmacol. Exp. Ther., 2009, 330(3), 902-910.
70. Desroches, J.; Guindon, J.; Lambert, C.; Beaulieu, P. Modulation of the anti-nociceptive effects of 2-arachidonoyl glycerol by peripherally administered FAAH and MGL inhibitors in a neuropathic pain model. Br. J. Pharmacol., 2008, 155(6), 913-924.
71. Comelli, F.; Giagnoni, G.; Bettoni, I.; Colleoni, M.; Costa, B. The inhibition of monoacylglycerol lipase by URB602 showed an antiinflammatory and anti-nociceptive effect in a murine model of acute inflammation. Br. J. Pharmacol., 2007, 152(5), 787-794.
72. Hanus, L.; Abu-Lafi, S.; Fride, E.; Breuer, A.; Vogel, Z.; Shalev, D.E.; Kustanovich, I.; Mechoulam, R. 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc. Natl. Acad. Sci. USA, 2001, 98(7), 3662-3665.
73. Richardson, D.; Ortori, C.A.; Chapman, V.; Kendall, D.A.; Barrett, D.A. Quantitative profiling of endocannabinoids and related compounds in rat brain using liquid chromatography-tandem electrospray ionization mass spectrometry. Anal. Biochem., 2007, 360(2), 216-226.
74. Bisogno, T.; Melck, D.; Bobrov, M.; Gretskaya, N.M.; Bezuglov, V.V.; De Petrocellis, L.; Di Marzo, V. N-acyl-dopamines: novel synthetic CB(1) cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. Biochem. J., 2000, 351(3), 817-824.
75. Huang, S.M.; Bisogno, T.; Trevisani, M.; Al-Hayani, A.; De Petrocellis, L.; Fezza, F.; Tognetto, M.; Petros, T.J.; Krey, J.F.; Chu, C.J.; Miller, J.D.; Davies, S.N.; Geppetti, P.; Walker, J.M.; Di Marzo, V. An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc. Natl. Acad. Sci. USA, 2002, 99(12), 8400-8405.
76. Kuehl, F.A.; Jacob, T.A.; Ganley, O.H.; Ormond, R.E.; Meisinger, M.A.P. The identification of N-2(hydroxyethyl)-palmitamide as a naturally occurring anti-inflammatory agent. J. Am. Chem. Soc., 1957, 79, 5577-5578.
77. Walker, J.M.; Krey, J.F.; Chu, C.J.; Huang, S.M. Endocannabinoids and related fatty acid derivatives in pain modulation. Chem. Phys. Lipids, 2002, 121(1-2), 159-172.
78. Bachur, N.R.; Masek, K.; Melmon, K.L.; Udenfriend, S. Fatty Acid Amides of Ethanolamine in Mammalian Tissues. J. Biol. Chem., 1965, 240(3), 1019-1024.
79. Kostadinova, R.; Wahli, W.; Michalik, L. PPARs in diseases: control mechanisms of inflammation. Curr. Med. Chem., 2005, 12(25), 2995-3009.
80. Lo Verme, J.; Fu, J.; Astarita, G.; La Rana, G.; Russo, R.; Calignano, A.; Piomelli, D. The nuclear receptor peroxisome proliferator- activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol. Pharmacol., 2005, 67(1), 15-19.
81. LoVerme, J.; Russo, R.; La Rana, G.; Fu, J.; Farthing, J.; Mattace- Raso, G.; Meli, R.; Hohmann, A.; Calignano, A.; Piomelli, D. Rapid broad-spectrum analgesia through activation of peroxisome proliferator-activated receptor-alpha. J. Pharmacol. Exp. Ther., 2006, 319(3), 1051-1061.
82. Bradshaw, H.B.; Walker, J.M. The expanding field of cannabimimetic and related lipid mediators. Br. J. Pharmacol., 2005, 144(4), 459-465.
83. Calignano, A.; La Rana, G.; Giuffrida, A.; Piomelli, D. Control of pain initiation by endogenous cannabinoids. Nature, 1998, 394(6690), 277-281.
84. Calignano, A.; La Rana, G.; Piomelli, D. Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamide. Eur. J. Pharmacol., 2001, 419(2-3), 191-198.
85. LoVerme, J.; La Rana, G.; Russo, R.; Calignano, A.; Piomelli, D. The search for the palmitoylethanolamide receptor. Life Sci., 2005, 77(14), 1685-1698.
86. Costa, B.; Comelli, F.; Bettoni, I.; Colleoni, M.; Giagnoni, G. The endogenous fatty acid amide, palmitoylethanolamide, has antiallodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: involvement of CB(1), TRPV1 and PPARgamma receptors and neurotrophic factors. Pain, 2008, 139(3), 541-550.
87. Fu, J.; Gaetani, S.; Oveisi, F.; Lo Verme, J.; Serrano, A.; Rodriguez De Fonseca, F.; Rosengarth, A.; Luecke, H.; Di Giacomo, B.; Tarzia, G.; Piomelli, D. Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. Nature, 2003, 425(6953), 90-93.
88. Rodriguez de Fonseca, F.; Navarro, M.; Gomez, R.; Escuredo, L.; Nava, F.; Fu, J.; Murillo-Rodriguez, E.; Giuffrida, A.; LoVerme, J.; Gaetani, S.; Kathuria, S.; Gall, C.; Piomelli, D. An anorexic lipid mediator regulated by feeding. Nature, 2001, 414(6860), 209-212.
89. Overton, H.A.; Babbs, A.J.; Doel, S.M.; Fyfe, M.C.; Gardner, L.S.; Griffin, G.; Jackson, H.C.; Procter, M.J.; Rasamison, C.M.; Tang- Christensen, M.; Widdowson, P.S.; Williams, G.M.; Reynet, C. Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents. Cell Metab., 2006, 3(3), 167-175.
90. Wang, X.; Miyares, R.L.; Ahern, G.P. Oleoylethanolamide excites vagal sensory neurones, induces visceral pain and reduces shortterm food intake in mice via capsaicin receptor TRPV1. J. Physiol., 2005, 564(Pt 2), 541-547.
91. Suardiaz, M.; Estivill-Torrus, G.; Goicoechea, C.; Bilbao, A.; Rodriguez de Fonseca, F. Analgesic properties of oleoylethanolamide (OEA) in visceral and inflammatory pain. Pain, 2007, 133(1-3), 99-110.
92. Sheskin, T.; Hanus, L.; Slager, J.; Vogel, Z.; Mechoulam, R. Structural requirements for binding of anandamide-type compounds to the brain cannabinoid receptor. J. Med. Chem., 1997, 40(5), 659-667.
93. Huang, S.M.; Bisogno, T.; Petros, T.J.; Chang, S.Y.; Zavitsanos, P.A.; Zipkin, R.E.; Sivakumar, R.; Coop, A.; Maeda, D.Y.; De Petrocellis, L.; Burstein, S.; Di Marzo, V.; Walker, J.M. Identification of a new class of molecules, the arachidonyl amino acids, and characterization of one member that inhibits pain. J. Biol. Chem., 2001, 276(46), 42639-42644.
94. Kohno, M.; Hasegawa, H.; Inoue, A.; Muraoka, M.; Miyazaki, T.; Oka, K.; Yasukawa, M. Identification of N-arachidonylglycine as the endogenous ligand for orphan G-protein-coupled receptor GPR18. Biochem. Biophys. Res. Commun., 2006, 347(3), 827-832.
95. Oh, D.Y.; Yoon, J.M.; Moon, M.J.; Hwang, J.I.; Choe, H.; Lee, J.Y.; Kim, J.I.; Kim, S.; Rhim, H.; O'Dell, D.K.; Walker, J.M.; Na, H.S.; Lee, M.G.; Kwon, H.B.; Kim, K.; Seong, J.Y. Identification of farnesyl pyrophosphate and N-arachidonylglycine as endogenous ligands for GPR92. J. Biol. Chem., 2008, 283(30), 21054-21064.
96. Vuong, L.A.; Mitchell, V.A.; Vaughan, C.W. Actions of Narachidonyl- glycine in a rat neuropathic pain model. Neuropharmacology, 2008, 54(1), 189-193.
97. Succar, R.; Mitchell, V.A.; Vaughan, C.W. Actions of Narachidonyl- glycine in a rat inflammatory pain model. Mol. Pain, 2007, 3, 24.
98. Burstein, S.H.; Huang, S.M.; Petros, T.J.; Rossetti, R.G.; Walker, J.M.; Zurier, R.B. Regulation of anandamide tissue levels by Narachidonylglycine. Biochem. Pharmacol., 2002, 64(7), 1147-1150.
99. Grazia Cascio, M.; Minassi, A.; Ligresti, A.; Appendino, G.; Burstein, S.; Di Marzo, V. A structure-activity relationship studyon N-arachidonoyl-amino acids as possible endogenous inhibitors of fatty acid amide hydrolase. Biochem. Biophys. Res. Commun., 2004, 314(1), 192-196.
100. Barbara, G.; Alloui, A.; Nargeot, J.; Lory, P.; Eschalier, A.; Bourinet, E.; Chemin, J. T-type calcium channel inhibition underlies the analgesic effects of the endogenous lipoamino acids. J. Neurosci., 2009, 29(42), 13106-13114.
101. Tanimura, A.; Yamazaki, M.; Hashimotodani, Y.; Uchigashima, M.; Kawata, S.; Abe, M.; Kita, Y.; Hashimoto, K.; Shimizu, T.; Watanabe, M.; Sakimura, K.; Kano, M. The endocannabinoid 2- arachidonoylglycerol produced by diacylglycerol lipase alpha mediates retrograde suppression of synaptic transmission. Neuron, 2010, 65(3), 320-327.
102. Cravatt, B.F.; Giang, D.K.; Mayfield, S.P.; Boger, D.L.; Lerner, R.A.; Gilula, N.B. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature, 1996, 384(6604), 83-87.
103. Bracey, M.H.; Hanson, M.A.; Masuda, K.R.; Stevens, R.C.; Cravatt, B.F. Structural adaptations in a membrane enzyme that terminates endocannabinoid signaling. Science, 2002, 298(5599), 1793-1796.
104. Mileni, M.; Garfunkle, J.; Ezzili, C.; Kimball, F.S.; Cravatt, B.F.; Stevens, R.C.; Boger, D.L. X-ray crystallographic analysis of alpha- ketoheterocycle inhibitors bound to a humanized variant of fatty acid amide hydrolase. J. Med. Chem., 2010, 53(1), 230-240.
105. Mileni, M.; Johnson, D.S.; Wang, Z.; Everdeen, D.S.; Liimatta, M.; Pabst, B.; Bhattacharya, K.; Nugent, R.A.; Kamtekar, S.; Cravatt, B.F.; Ahn, K.; Stevens, R.C. Structure-guided inhibitor design for human FAAH by interspecies active site conversion. Proc. Natl. Acad. Sci. USA, 2008, 105(35), 12820-12824.
106. Patricelli, M.P.; Lovato, M.A.; Cravatt, B.F. Chemical and mutagenic investigations of fatty acid amide hydrolase: evidence for a family of serine hydrolases with distinct catalytic properties. Biochemistry, 1999, 38(31), 9804-9812.
107. Seierstad, M.; Breitenbucher, J.G. Discovery and development of fatty acid amide hydrolase (FAAH) inhibitors. J. Med. Chem., 2008, 51(23), 7327-7343.
108. Giang, D.K.; Cravatt, B.F. Molecular characterization of human and mouse fatty acid amide hydrolases. Proc. Natl. Acad. Sci. USA, 1997, 94(6), 2238-2242.
109. Egertova, M.; Cravatt, B.F.; Elphick, M.R. Comparative analysis of fatty acid amide hydrolase and cb(1) cannabinoid receptor expression in the mouse brain: evidence of a widespread role for fatty acid amide hydrolase in regulation of endocannabinoid signaling. Neuroscience, 2003, 119(2), 481-496.
110. Egertova, M.; Giang, D.K.; Cravatt, B.F.; Elphick, M.R. A new perspective on cannabinoid signalling: complementary localization of fatty acid amide hydrolase and the CB1 receptor in rat brain. Proc. Biol. Sci., 1998, 265(1410), 2081-2085.
111. Gulyas, A.I.; Cravatt, B.F.; Bracey, M.H.; Dinh, T.P.; Piomelli, D.; Boscia, F.; Freund, T.F. Segregation of two endocannabinoidhydrolyzing enzymes into pre- and postsynaptic compartments in the rat hippocampus, cerebellum and amygdala. Eur. J. Neurosci., 2004, 20(2), 441-458.
112. Willoughby, K.A.; Moore, S.F.; Martin, B.R.; Ellis, E.F. The biodisposition and metabolism of anandamide in mice. J. Pharmacol. Exp. Ther., 1997, 282(1), 243-247.
113. Lichtman, A.H.; Shelton, C.C.; Advani, T.; Cravatt, B.F. Mice lacking fatty acid amide hydrolase exhibit a cannabinoid receptormediated phenotypic hypoalgesia. Pain, 2004, 109(3), 319-327.
114. Cravatt, B.F.; Saghatelian, A.; Hawkins, E.G.; Clement, A.B.; Bracey, M.H.; Lichtman, A.H. Functional disassociation of the central and peripheral fatty acid amide signaling systems. Proc. Natl. Acad. Sci. USA, 2004, 101(29), 10821-10826.
115. Wei, B.Q.; Mikkelsen, T.S.; McKinney, M.K.; Lander, E.S.; Cravatt, B.F. A second fatty acid amide hydrolase with variable distribution among placental mammals. J. Biol. Chem., 2006, 281(48), 36569-36578.
116. Karbarz, M.J.; Luo, L.; Chang, L.; Tham, C.S.; Palmer, J.A.; Wilson, S.J.; Wennerholm, M.L.; Brown, S.M.; Scott, B.P.; Apodaca, R.L.; Keith, J.M.; Wu, J.; Breitenbucher, J.G.; Chaplan, S.R.; Webb, M. Biochemical and biological properties of 4-(3-phenyl- [1,2,4] thiadiazol-5-yl)-piperazine-1-carboxylic acid phenylamide, a mechanism-based inhibitor of fatty acid amide hydrolase. Anesth. Analg., 2009, 108(1), 316-329.
117. Di Marzo, V.; Bisogno, T.; Sugiura, T.; Melck, D.; De Petrocellis, L. The novel endogenous cannabinoid 2-arachidonoylglycerol is inactivated by neuronal- and basophil-like cells: connections with anandamide. Biochem. J., 1998, 331(1), 15-19.
118. Goparaju, S.K.; Ueda, N.; Yamaguchi, H.; Yamamoto, S. Anandamide amidohydrolase reacting with 2-arachidonoylglycerol, another cannabinoid receptor ligand. FEBS Lett., 1998, 422(1), 69-73.
119. Palmer, J.A.; Higuera, E.S.; Chang, L.; Chaplan, S.R. Fatty acid amide hydrolase inhibition enhances the anti-allodynic actions of endocannabinoids in a model of acute pain adapted for the mouse. Neuroscience, 2008, 154(4), 1554-1561.
120. Dinh, T.P.; Carpenter, D.; Leslie, F.M.; Freund, T.F.; Katona, I.; Sensi, S.L.; Kathuria, S.; Piomelli, D. Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc. Natl. Acad. Sci. USA, 2002, 99(16), 10819-10824.
121. Dinh, T.P.; Kathuria, S.; Piomelli, D. RNA interference suggests a primary role for monoacylglycerol lipase in the degradation of the endocannabinoid 2-arachidonoylglycerol. Mol. Pharmacol., 2004, 66(5), 1260-1264.
122. Kathuria, S.; Gaetani, S.; Fegley, D.; Valino, F.; Duranti, A.; Tontini, A.; Mor, M.; Tarzia, G.; La Rana, G.; Calignano, A.; Giustino, A.; Tattoli, M.; Palmery, M.; Cuomo, V.; Piomelli, D. Modulation of anxiety through blockade of anandamide hydrolysis. Nat. Med., 2003, 9(1), 76-81.
123. Long, J.Z.; Li, W.; Booker, L.; Burston, J.J.; Kinsey, S.G.; Schlosburg, J.E.; Pavon, F.J.; Serrano, A.M.; Selley, D.E.; Parsons, L.H.; Lichtman, A.H.; Cravatt, B.F. Selective blockade of 2- arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. Nat. Chem. Biol., 2009, 5(1), 37-44.
124. Blankman, J.L.; Simon, G.M.; Cravatt, B.F. A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2- arachidonoylglycerol. Chem. Biol., 2007, 14(12), 1347-1356.
125. Tsuboi, K.; Sun, Y.X.; Okamoto, Y.; Araki, N.; Tonai, T.; Ueda, N. Molecular characterization of N-acylethanolamine-hydrolyzing acid amidase, a novel member of the choloylglycine hydrolase family with structural and functional similarity to acid ceramidase. J. Biol. Chem., 2005, 280(12), 11082-11092.
126. Ueda, N.; Yamanaka, K.; Yamamoto, S. Purification and characterization of an acid amidase selective for Npalmitoylethanolamine, a putative endogenous anti-inflammatory substance. J. Biol. Chem., 2001, 276(38), 35552-35557.
127. Solorzano, C.; Zhu, C.; Battista, N.; Astarita, G.; Lodola, A.; Rivara, S.; Mor, M.; Russo, R.; Maccarrone, M.; Antonietti, F.; Duranti, A.; Tontini, A.; Cuzzocrea, S.; Tarzia, G.; Piomelli, D. Selective N-acylethanolamine-hydrolyzing acid amidase inhibition reveals a key role for endogenous palmitoylethanolamide in inflammation. Proc. Natl. Acad. Sci. USA, 2009, 106(49), 20966-20971.
128. Muccioli, G.G.; Xu, C.; Odah, E.; Cudaback, E.; Cisneros, J.A.; Lambert, D.M.; Lopez Rodriguez, M.L.; Bajjalieh, S.; Stella, N. Identification of a novel endocannabinoid-hydrolyzing enzyme expressed by microglial cells. J. Neurosci., 2007, 27(11), 2883-2889.
129. Li, W.; Blankman, J.L.; Cravatt, B.F. A functional proteomic strategy to discover inhibitors for uncharacterized hydrolases. J. Am. Chem. Soc., 2007, 129(31), 9594-9595.
130. Ahn, K.; Johnson, D.S.; Cravatt, B.F. Fatty acid amide hydrolase as a potential therapeutic target for the treatment of pain and CNS disorders. Expert Opin. Drug Discov., 2009, 4(7), 763-784.
131. Petrosino, S.; Di Marzo, V. FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels. Curr. Opin. Investig. Drugs, 2010, 11(1), 51-62.
132. Maione, S.; De Petrocellis, L.; de Novellis, V.; Moriello, A.S.; Petrosino, S.; Palazzo, E.; Rossi, F.S.; Woodward, D.F.; Di Marzo, V. Analgesic actions of N-arachidonoyl-serotonin, a fatty acid amide hydrolase inhibitor with antagonistic activity at vanilloid TRPV1 receptors. Br. J. Pharmacol., 2007, 150(6), 766-781.
133. de Novellis, V.; Palazzo, E.; Rossi, F.; De Petrocellis, L.; Petrosino, S.; Guida, F.; Luongo, L.; Migliozzi, A.; Cristino, L.; Marabese, I.; Starowicz, K.; Di Marzo, V.; Maione, S. The analgesic effect of N-arachidonoyl-serotonin, a FAAH inhibitor and TRPV1 receptor antagonist, associated with changes in rostral ventromedial medulla and locus coeruleus cell activity in rats. Neuropharmacology, 2008, 55(7), 1105-1113.
134. Costa, B.; Bettoni, I.; Petrosino, S.; Comelli, F.; Giagnoni, G.; Di Marzo, V. The dual fatty acid amide hydrolase/TRPV1 blocker, Narachidonoyl- serotonin, relieves carrageenan-induced inflammation and hyperalgesia in mice. Pharmacol. Res., 2010, 61(6), 537-546.
135. Costa, B.; Siniscalco, D.; Trovato, A.E.; Comelli, F.; Sotgiu, M.L.; Colleoni, M.; Maione, S.; Rossi, F.; Giagnoni, G. AM404, an inhibitor of anandamide uptake, prevents pain behaviour and modulates cytokine and apoptotic pathways in a rat model of neuropathic pain. Br. J. Pharmacol., 2006, 148(7), 1022-1032.
136. Mitchell, V.A.; Greenwood, R.; Jayamanne, A.; Vaughan, C.W. Actions of the endocannabinoid transport inhibitor AM404 in neuropathic and inflammatory pain models. Clin. Exp. Pharmacol. Physiol., 2007, 34(11), 1186-1190.
137. Hasanein, P. The endocannabinoid transport inhibitor AM404 modulates nociception in cholestasis. Neurosci. Lett., 2009, 462(3), 230-234.
138. Wallace, V.C.; Segerdahl, A.R.; Lambert, D.M.; Vandevoorde, S.; Blackbeard, J.; Pheby, T.; Hasnie, F.; Rice, A.S. The effect of the palmitoylethanolamide analogue, palmitoylallylamide (L-29) on pain behaviour in rodent models of neuropathy. Br. J. Pharmacol., 2007, 151(7), 1117-1128.
139. Di Marzo, V.; Breivogel, C.; Bisogno, T.; Melck, D.; Patrick, G.; Tao, Q.; Szallasi, A.; Razdan, R.K.; Martin, B.R. Neurobehavioral activity in mice of N-vanillyl-arachidonyl-amide. Eur. J. Pharmacol., 2000, 406(3), 363-374.
140. Di Marzo, V.; Griffin, G.; De Petrocellis, L.; Brandi, I.; Bisogno, T.; Williams, W.; Grier, M.C.; Kulasegram, S.; Mahadevan, A.; Razdan, R.K.; Martin, B.R. A structure/activity relationship study on arvanil, an endocannabinoid and vanilloid hybrid. J. Pharmacol. Exp. Ther., 2002, 300(3), 984-991.
141. Brooks, J.W.; Pryce, G.; Bisogno, T.; Jaggar, S.I.; Hankey, D.J.; Brown, P.; Bridges, D.; Ledent, C.; Bifulco, M.; Rice, A.S.; Di Marzo, V.; Baker, D. Arvanil-induced inhibition of spasticity and persistent pain: evidence for therapeutic sites of action different from the vanilloid VR1 receptor and cannabinoid CB(1)/CB(2) receptors. Eur. J. Pharmacol., 2002, 439(1-3), 83-92.
142. Haller, V.L.; Cichewicz, D.L.; Welch, S.P. Non-cannabinoid CB1, non-cannabinoid CB2 antinociceptive effects of several novel compounds in the PPQ stretch test in mice. Eur. J. Pharmacol., 2006, 546(1-3), 60-68.
143. Boger, D.L.; Miyauchi, H.; Du, W.; Hardouin, C.; Fecik, R.A.; Cheng, H.; Hwang, I.; Hedrick, M.P.; Leung, D.; Acevedo, O.; Guimaraes, C.R.; Jorgensen, W.L.; Cravatt, B.F. Discovery of a potent, selective, and efficacious class of reversible alphaketoheterocycle inhibitors of fatty acid amide hydrolase effective as analgesics. J. Med. Chem., 2005, 48(6), 1849-1856.
144. Lichtman, A.H.; Leung, D.; Shelton, C.C.; Saghatelian, A.; Hardouin, C.; Boger, D.L.; Cravatt, B.F. Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: evidence for an unprecedented combination of potency and selectivity. J. Pharmacol. Exp. Ther., 2004, 311(2), 441-448.
145. Chang, L.; Luo, L.; Palmer, J.A.; Sutton, S.; Wilson, S.J.; Barbier, A.J.; Breitenbucher, J.G.; Chaplan, S.R.; Webb, M. Inhibition of fatty acid amide hydrolase produces analgesia by multiple mechanisms. Br. J. Pharmacol., 2006, 148(1), 102-113.
146. Naidu, P.S.; Booker, L.; Cravatt, B.F.; Lichtman, A.H. Synergy between enzyme inhibitors of fatty acid amide hydrolase and cyclooxygenase in visceral nociception. J. Pharmacol. Exp. Ther., 2009, 329(1), 48-56.
147. Leung, D.; Hardouin, C.; Boger, D.L.; Cravatt, B.F. Discovering potent and selective reversible inhibitors of enzymes in complex proteomes. Nat. Biotechnol., 2003, 21(6), 687-691.
148. Zhang, D.; Saraf, A.; Kolasa, T.; Bhatia, P.; Zheng, G.Z.; Patel, M.; Lannoye, G.S.; Richardson, P.; Stewart, A.; Rogers, J.C.; Brioni, J.D.; Surowy, C.S. Fatty acid amide hydrolase inhibitors display broad selectivity and inhibit multiple carboxylesterases as offtargets. Neuropharmacology, 2007, 52(4), 1095-1105.
149. Ahn, K.; Johnson, D.S.; Fitzgerald, L.R.; Liimatta, M.; Arendse, A.; Stevenson, T.; Lund, E.T.; Nugent, R.A.; Nomanbhoy, T.K.; Alexander, J.P.; Cravatt, B.F. Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity. Biochemistry, 2007, 46(45), 13019-13030.
150. Russo, R.; Loverme, J.; La Rana, G.; Compton, T.R.; Parrott, J.; Duranti, A.; Tontini, A.; Mor, M.; Tarzia, G.; Calignano, A.; Piomelli, D. The fatty acid amide hydrolase inhibitor URB597 (cyclohexylcarbamic acid 3'-carbamoylbiphenyl-3-yl ester) reduces neuropathic pain after oral administration in mice. J. Pharmacol. Exp. Ther., 2007, 322(1), 236-242.
151. Storr, M.A.; Keenan, C.M.; Emmerdinger, D.; Zhang, H.; Yuce, B.; Sibaev, A.; Massa, F.; Buckley, N.E.; Lutz, B.; Goke, B.; Brand, S.; Patel, K.D.; Sharkey, K.A. Targeting endocannabinoid degradation protects against experimental colitis in mice: involvement of CB1 and CB2 receptors. J. Mol. Med., 2008, 86(8), 925-936.
152. Hasanein, P.; Shahidi, S.; Komaki, A.; Mirazi, N. Effects of URB597 as an inhibitor of fatty acid amide hydrolase on modulation of nociception in a rat model of cholestasis. Eur. J. Pharmacol., 2008, 591(1-3), 132-135.
153. Sagar, D.R.; Kendall, D.A.; Chapman, V. Inhibition of fatty acid amide hydrolase produces PPAR-alpha-mediated analgesia in a rat model of inflammatory pain. Br. J. Pharmacol., 2008, 155(8), 1297-1306.
154. Jhaveri, M.D.; Richardson, D.; Robinson, I.; Garle, M.J.; Patel, A.; Sun, Y.; Sagar, D.R.; Bennett, A.J.; Alexander, S.P.; Kendall, D.A.; Barrett, D.A.; Chapman, V. Inhibition of fatty acid amide hydrolase and cyclooxygenase-2 increases levels of endocannabinoid related molecules and produces analgesia via peroxisome proliferator- activated receptor-alpha in a model of inflammatory pain. Neuropharmacology, 2008, 55(1), 85-93.
155. Khasabova, I.A.; Khasabov, S.G.; Harding-Rose, C.; Coicou, L.G.; Seybold, B.A.; Lindberg, A.E.; Steevens, C.D.; Simone, D.A.; Seybold, V.S. A decrease in anandamide signaling contributes to the maintenance of cutaneous mechanical hyperalgesia in a model of bone cancer pain. J. Neurosci., 2008, 28(44), 11141-11152.
156. Sit, S.Y.; Conway, C.; Bertekap, R.; Xie, K.; Bourin, C.; Burris, K.; Deng, H. Novel inhibitors of fatty acid amide hydrolase. Bioorg. Med. Chem. Lett., 2007, 17(12), 3287-3291.
157. Johnson, D.S.; Ahn, K.; Kesten, S.; Lazerwith, S.E.; Song, Y.; Morris, M.; Fay, L.; Gregory, T.; Stiff, C.; Dunbar, J.B., Jr.; Liimatta, M.; Beidler, D.; Smith, S.; Nomanbhoy, T.K.; Cravatt, B.F. Benzothiophene piperazine and piperidine urea inhibitors of fatty acid amide hydrolase (FAAH). Bioorg. Med. Chem. Lett., 2009, 19(10), 2865-2869.
158. Keith, J.M.; Apodaca, R.; Xiao, W.; Seierstad, M.; Pattabiraman, K.; Wu, J.; Webb, M.; Karbarz, M.J.; Brown, S.; Wilson, S.; Scott, B.; Tham, C.S.; Luo, L.; Palmer, J.; Wennerholm, M.; Chaplan, S.; Breitenbucher, J.G. Thiadiazolopiperazinyl ureas as inhibitors of fatty acid amide hydrolase. Bioorg. Med. Chem. Lett., 2008, 18(17), 4838-4843.
159. Alexander, J.P.; Cravatt, B.F. Mechanism of carbamate inactivation of FAAH: implications for the design of covalent inhibitors and in vivo functional probes for enzymes. Chem. Biol., 2005, 12(11), 1179-1187.
160. Hart, T.; Macias, A.T.; Benwell, K.; Brooks, T.; D'Alessandro, J.; Dokurno, P.; Francis, G.; Gibbons, B.; Haymes, T.; Kennett, G.; Lightowler, S.; Mansell, H.; Matassova, N.; Misra, A.; Padfield, A.; Parsons, R.; Pratt, R.; Robertson, A.; Walls, S.; Wong, M.; Roughley, S. Fatty acid amide hydrolase inhibitors. Surprising selectivity of chiral azetidine ureas. Bioorg. Med. Chem. Lett., 2009, 19(15), 4241-4244.
161. Wang, J.L.; Bowen, S.J.; Schweitzer, B.A.; Madsen, H.M.; McDonald, J.; Pelc, M.J.; Tenbrink, R.E.; Beidler, D.; Thorarensen, A. Structure based design of novel irreversible FAAH inhibitors. Bioorg. Med. Chem. Lett., 2009, 19(20), 5970-5974.
162. Saario, S.M.; Salo, O.M.; Nevalainen, T.; Poso, A.; Laitinen, J.T.; Jarvinen, T.; Niemi, R. Characterization of the sulfhydryl-sensitive site in the enzyme responsible for hydrolysis of 2-arachidonoylglycerol in rat cerebellar membranes. Chem. Biol., 2005, 12(6), 649-656.
163. Burston, J.J.; Sim-Selley, L.J.; Harloe, J.P.; Mahadevan, A.; Razdan, R.K.; Selley, D.E.; Wiley, J.L. N-arachidonyl maleimide potentiates the pharmacological and biochemical effects of the endocannabinoid 2-arachidonylglycerol through inhibition of monoacylglycerol lipase. J. Pharmacol. Exp. Ther., 2008, 327(2), 546-553.
164. Makara, J.K.; Mor, M.; Fegley, D.; Szabo, S.I.; Kathuria, S.; Astarita, G.; Duranti, A.; Tontini, A.; Tarzia, G.; Rivara, S.; Freund, T.F.; Piomelli, D. Selective inhibition of 2-AG hydrolysis enhances endocannabinoid signaling in hippocampus. Nat. Neurosci., 2005, 8(9), 1139-1141.
165. Suplita, R.L., 2nd; Gutierrez, T.; Fegley, D.; Piomelli, D.; Hohmann, A.G. Endocannabinoids at the spinal level regulate, but do not mediate, nonopioid stress-induced analgesia. Neuropharmacology, 2006, 50(3), 372-379.
166. Guindon, J.; Desroches, J.; Beaulieu, P. The antinociceptive effects of intraplantar injections of 2-arachidonoyl glycerol are mediatedby cannabinoid CB2 receptors. Br. J. Pharmacol., 2007, 150(6), 693-701.
167. Vandevoorde, S.; Jonsson, K.O.; Labar, G.; Persson, E.; Lambert, D.M.; Fowler, C.J. Lack of selectivity of URB602 for 2- oleoylglycerol compared to anandamide hydrolysis in vitro. Br. J. Pharmacol., 2007, 150(2), 186-191.
168. Saario, S.M.; Palomaki, V.; Lehtonen, M.; Nevalainen, T.; Jarvinen, T.; Laitinen, J.T. URB754 has no effect on the hydrolysis or signaling capacity of 2-AG in the rat brain. Chem. Biol., 2006, 13(8), 811-814.
169. Schlosburg, J.E.; Carlson, B.L.; Ramesh, D.; Abdullah, R.A.; Long, J.Z.; Cravatt, B.F.; Lichtman, A.H. Inhibitors of endocannabinoidmetabolizing enzymes reduce precipitated withdrawal responses in THC-dependent mice. AAPS J., 2009, 11(2), 342-352.
170. Long, J.Z.; Nomura, D.K.; Vann, R.E.; Walentiny, D.M.; Booker, L.; Jin, X.; Burston, J.J.; Sim-Selley, L.J.; Lichtman, A.H.; Wiley, J.L.; Cravatt, B.F. Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo. Proc. Natl. Acad. Sci. USA, 2009, 106(48), 20270-20275.
171. Long, J.Z.; Jin, X.; Adibekian, A.; Li, W.; Cravatt, B.F. Characterization of tunable piperidine and piperazine carbamates as inhibitors of endocannabinoid hydrolases. J. Med. Chem., 2010, 53(4), 1830-1842.
172. Patel, S.; Hillard, C.J. Cannabinoid CB(1) receptor agonists produce cerebellar dysfunction in mice. J. Pharmacol. Exp. Ther., 2001, 297(2), 629-637.
173. Bisogno, T.; Ortar, G.; Petrosino, S.; Morera, E.; Palazzo, E.; Nalli, M.; Maione, S.; Di Marzo, V. Development of a potent inhibitor of 2-arachidonoylglycerol hydrolysis with antinociceptive activity in vivo. Biochim. Biophys. Acta, 2009, 1791(1), 53-60.
174. King, A.R.; Dotsey, E.Y.; Lodola, A.; Jung, K.M.; Ghomian, A.; Qiu, Y.; Fu, J.; Mor, M.; Piomelli, D. Discovery of potent and reversible monoacylglycerol lipase inhibitors. Chem. Biol., 2009, 16(10), 1045-1052.
175. King, A.R.; Lodola, A.; Carmi, C.; Fu, J.; Mor, M.; Piomelli, D. A critical cysteine residue in monoacylglycerol lipase is targeted by a new class of isothiazolinone-based enzyme inhibitors. Br. J. Pharmacol., 2009, 157(6), 974-983.